Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed?
Precigen (PGEN) experienced a 7.4% stock increase after reporting a significant rise in 2025 revenue to US$9.68 million, alongside a widened net loss of US$250.64 million. This article examines how these results, particularly the substantial net loss, impact the investment outlook for Precigen and its primary therapy, PAPZIMEOS. While revenue growth is encouraging, the increased losses highlight the importance of successful commercialization and raise concerns about short-term dilution and financing risks.